A cell and a vesicle are not the same category of thing
A stem cell is a living cell capable of dividing and, under the right laboratory conditions, differentiating into other cell types. An exosome is a nanoscale, membrane-bound vesicle released by a cell; it has no nucleus, cannot divide, and is not alive in the way a cell is. These are different categories of biological material, and marketing language that uses them interchangeably obscures what a given product actually contains.
The terminology gets looser than that in practice. MISEV2023, the field's current reporting guideline for extracellular vesicle research, recommends using the broader term extracellular vesicle for a preparation unless exosome-specific biogenesis has been demonstrated for that particular product. A preparation marketed as exosomes without that demonstration is, by this standard, more accurately described as a mixed EV population, and the label alone doesn't settle which is which.
How stem cell products and exosome products are actually manufactured
A stem cell-based product requires maintaining living cells through recovery, culture, and shipment, with viability as a central manufacturing concern and a cold chain built around keeping cells alive until use.
Bio Xsomes is derived from a specified progenitor endothelial cell line; the source cells are not what ships, only the vesicle fraction they release into culture medium is isolated and concentrated into the finished product. Bio EX and Bio AER are described by the supplier as umbilical cord-derived. Request each product's specific processing documentation rather than assuming one manufacturing description applies across the category.
Why FDA treats the two categories differently
FDA has stated plainly that there are no FDA-approved exosome products on the market. Exosome and EV preparations are generally regulated as biologic drugs under section 351 of the PHS Act, a different pathway from the section 361 HCT/P framework that governs minimally manipulated tissue allografts.
The HCT/P evaluation at 21 CFR 1271.10, including whether a given use qualifies as minimal manipulation and homologous use with no systemic effect, applies to products like cord tissue allografts, not to exosome products. Whichever category a product falls into, the determination of its regulatory pathway and whether a specific intended use is appropriate under it belongs to the physician and their own regulatory counsel, not to a supplier's product label.
What characterization data documents, and what it doesn't
Analytical methods like nanoparticle tracking analysis, ELISA, and single particle interferometric reflectance imaging sensing document identity: that particles of a given size and concentration are present, and that tetraspanin surface markers associated with exosomes, such as CD9 and CD81, were identified on them. Growth factor and cytokine panels reported alongside that data describe what is measurable in the preparation.
None of that is evidence of what a preparation does once used. A supplier that cites composition or characterization data as though it were outcome data is making exactly the kind of category error this comparison is meant to flag: identity and physical characteristics are not the same claim as effect, and legitimate documentation keeps the two clearly separate.
Vocabulary a legitimate exosome or EV product's documentation should use
The clearest sign of well-documented exosome or EV marketing is specificity, not enthusiasm.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
- The term extracellular vesicle or exosome used consistently with a stated isolation and characterization method, not applied loosely to any cell-derived preparation.
- A named, specific source cell line, rather than a vague description of origin.
- Particle concentration and marker data reported as analytical findings, not as functional or outcome claims.
- An explicit statement that regulatory classification and clinical use decisions are for the buyer's physician and regulatory counsel to determine.
Frequently asked questions
Are exosomes a type of stem cell?+
No. An exosome is a vesicle released by a cell, not a cell itself, and it cannot divide or differentiate the way a stem cell can.
Can an exosome product be marketed as FDA approved?+
No. FDA has stated there are no FDA-approved exosome products. Any claim suggesting otherwise should be checked directly against FDA's own published materials.
Does a higher particle-per-mL concentration mean a product is more effective?+
Particle concentration is an analytical measurement describing what's in the preparation, not a claim about clinical effect. We don't make comparative efficacy claims, and recommend asking for the laboratory method behind any number before relying on it.
Who determines whether an exosome product fits a clinic's intended use?+
The physician, together with their own regulatory counsel, since exosome products fall under a different regulatory pathway than tissue allografts and intended-use decisions are clinical and legal judgments, not something a supplier can determine.